NEWS
invIOs’s EPiC cell therapy platform to progress development of novel CAR-T cell approach against lung cancer with Medical University of Innsbruck
Lessons from the clinic: Checkpoint blockade, biomarkers, and the future of individualized solid tumor treatments
Clinical trials: From bench to bedside to improve outcomes for cancer patients
Cancer – the hallmarks and beyond
Three questions to Mario Kuttke, Head of Cell Therapy
The race against cancer – targeting Cbl-b in cellular therapy
Three questions to Alexander Dohnal, Head of Preclinical Development
RNA – in the midst of a medical revolution
Ribonucleic acid (RNA) therapies are promising to change the way we treat diseases. From cancer therapies to vaccines and treatments for genetic diseases, the opportunities are almost infinite.
Unlocking the master checkpoint of cancer immunity
Our knowledge of cancer is growing daily, bringing with it new treatment strategies. As mentioned previously (here) novel immunotherapies are at the forefront of cancer research. The immune activating monoclonal…
Three questions to Romana Gugenberger, Chief Medical and Scientific Officer
1. Despite novel immune-therapies against cancer there are still non-responders and relapses. Why is that? Romana Gugenberger: Tumors are heterogeneous. Additionally, tumors are not static but evolve. Once a response…
The immune system’s fight against cancer
Cancer is the second leading cause of death worldwide. Obviously, the complex cancer biology and simultaneous failure of our body to halt the transformation of a normal cell into cancer…
Perspectives: The Cancer Revolution
Despite recent advances in the treatment of cancer, the disease remains a leading cause of death by disease worldwide1. It is reported that one in two people will be diagnosed…
